Core Viewpoint - The acquisition of 100% equity in Shanghai Siyuan Lishi by Meili Tianyuan Medical Health is a strategic move to enhance its position in the high-end beauty service industry in China, with a total consideration of RMB 1.25 billion (approximately HKD 1.369 billion) [1][2]. Group 1: Acquisition Details - The agreement involves the conditional sale of shares by SYL Holding and Shanghai Anyan, with Meili Tianyuan Medical Health and Shanghai Meili Tianyuan as the buyers [1]. - The acquisition will result in the issuance of 15.7981 million consideration shares, representing approximately 6.70% of the total issued shares as of the announcement date [1]. - The company will apply for the listing and trading of the consideration shares on the Stock Exchange [1]. Group 2: Target Company Overview - The target company, established in December 2009, is a leading brand in China's high-end beauty service sector, known for its skincare products and services [2]. - As of June 30, 2025, the target company operates 163 beauty stores and 19 medical beauty clinics across 48 cities in China, with over 90% of its revenue coming from first-tier and new first-tier cities [2]. - According to Frost & Sullivan, the target company's brand ranks as the third-largest beauty service brand in China based on 2024 revenue [2]. Group 3: Strategic Implications - This acquisition marks a significant milestone for the company, following its successful acquisition of Nairui'er in 2024, and is expected to reshape the competitive landscape of the high-end beauty industry in high-tier cities [3]. - Post-acquisition, the company's store network will expand to 734 locations, significantly increasing its membership base [3]. - The integration will leverage five core capabilities, including chain management and AI-driven transformation, to maximize synergies and enhance revenue and profit growth [3].
美丽田园医疗健康(02373)以12.5亿元收购上海思妍丽实业100%股份 抢占高线城市高质美容制高点